ArticleInfection & chemotherapy2025
Role of Treatment with Remdesivir on the Early Readmission of Patients Affected by Nosocomial Coronavirus Disease 2019.
Article in Infection & chemotherapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Increase in Healthcare-Associated Infections: Is COVID-19 Responsible? A Narrative Review.Microorganisms · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe patients affected by hospital-acquired coronavirus disease 2019 (HA-COVID-19) who were readmitted in hospital within 60 days had worse prognosis and mortality. In this study the aim was the assessment of early readmission rate in HA-COVID-19 and the role of remdesivir treatment. MATERIALS AND
methodsThis observational retrospective study included patients with HA-COVID-19 hospitalized in different wards between Jan 2021 and Mar 2022. Early readmission rate was determined. A multivariate logistic regression was made to determine the predictive factors for re-hospitalization.
resultsA total of 190 patients with a confirmed diagnosis of HA-COVID-19 were included. Early readmission was documented in 22 patients (11.6%) with a consequent mortality rate of 22.7%. In multivariate analysis, the following factors were predictive of readmission: chronic pulmonary disease (odds ratio [OR], 3.187; 95% confidence interval [CI], 2.145-11.228;
conclusionReadmission cumulative rate was about one tenth with higher mortality. The remdesivir use in the first hospitalization leads to significant reduction in the odds of readmission.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.